OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.
- DOI
- 10.1007/s10549-026-07944-2
- Published
- 2026 Mar 30
- Container
- Breast cancer research and treatment
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10549-026-07944-2,
title = {OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.},
author = {Rugo HS and Pluard TJ and Sharma P and Melisko M and Al-Jazayrly G and Ji Y and Vidula N and Ellerton J and Smakal M and Zimovjanova M and Weng D},
year = {2026},
journal = {Breast cancer research and treatment},
doi = {10.1007/s10549-026-07944-2},
url = {https://doi.org/10.1007/s10549-026-07944-2}
}RIS
TY - JOUR TI - OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer. AU - Rugo HS AU - Pluard TJ AU - Sharma P AU - Melisko M AU - Al-Jazayrly G AU - Ji Y AU - Vidula N AU - Ellerton J AU - Smakal M AU - Zimovjanova M AU - Weng D PY - 2026 JO - Breast cancer research and treatment DO - 10.1007/s10549-026-07944-2 UR - https://doi.org/10.1007/s10549-026-07944-2 ER -
APA
HS, R., TJ, P., P, S., M, M., G, A., Y, J., N, V., J, E., M, S., M, Z., & D, W. (2026). OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-026-07944-2
Source records
- pubmed · retrieved 2026-09-25T09:25:27.415Z